Trial Profile
A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2022
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 20 Aug 2021 Status changed from active, no longer recruiting to completed.
- 01 Mar 2021 Results (as of 15 Jan 2018) published in the Cancer Science
- 03 Feb 2020 Planned End Date changed from 30 Nov 2019 to 1 Sep 2020.